These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ; Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505 [TBL] [Abstract][Full Text] [Related]
4. Effect of apolipoprotein E ε4 allele on the progression of cognitive decline in the early stage of Alzheimer's disease. Suzuki K; Hirakawa A; Ihara R; Iwata A; Ishii K; Ikeuchi T; Sun CK; Donohue M; Iwatsubo T; Alzheimers Dement (N Y); 2020; 6(1):e12007. PubMed ID: 32211510 [TBL] [Abstract][Full Text] [Related]
5. Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study. Yagi T; Kanekiyo M; Ito J; Ihara R; Suzuki K; Iwata A; Iwatsubo T; Aoshima K; ; Alzheimers Dement (N Y); 2019; 5():364-373. PubMed ID: 31440579 [TBL] [Abstract][Full Text] [Related]
7. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL; Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169 [TBL] [Abstract][Full Text] [Related]
8. APOE-ε4 modulates the association between regional amyloid deposition and cognitive performance in cognitively unimpaired middle-aged individuals. Brugulat-Serrat A; Sánchez-Benavides G; Cacciaglia R; Salvadó G; Shekari M; Collij LE; Buckley C; van Berckel BNM; Perissinotti A; Niñerola-Baizán A; Milà-Alomà M; Vilor-Tejedor N; Operto G; Falcon C; Grau-Rivera O; Arenaza-Urquijo EM; Minguillón C; Fauria K; Molinuevo JL; Suárez-Calvet M; Gispert JD; EJNMMI Res; 2023 Mar; 13(1):18. PubMed ID: 36856866 [TBL] [Abstract][Full Text] [Related]
9. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum. Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT; Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664 [TBL] [Abstract][Full Text] [Related]
10. Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change. Soldan A; Pettigrew C; Cai Q; Wang MC; Moghekar AR; O'Brien RJ; Selnes OA; Albert MS; JAMA Neurol; 2016 Jun; 73(6):698-705. PubMed ID: 27064267 [TBL] [Abstract][Full Text] [Related]
11. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study. Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM; J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495 [TBL] [Abstract][Full Text] [Related]
12. Cohort-Specific Optimization of Models Predicting Preclinical Alzheimer's Disease, to Enhance Screening Performance in the Middle of Preclinical Alzheimer's Disease Clinical Studies. Sato K; Mano T; Ihara R; Suzuki K; Niimi Y; Toda T; Iwatsubo T; Iwata A J Prev Alzheimers Dis; 2021; 8(4):503-512. PubMed ID: 34585226 [TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O; JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367 [TBL] [Abstract][Full Text] [Related]
14. ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease - Study Protocol and Baseline Characteristics. Snellman A; Ekblad LL; Koivumäki M; Lindgrén N; Tuisku J; Perälä M; Kallio L; Lehtonen R; Saunavaara V; Saunavaara J; Oikonen V; Aarnio R; Löyttyniemi E; Parkkola R; Karrasch M; Zetterberg H; Blennow K; Rinne JO Front Neurol; 2022; 13():826423. PubMed ID: 35222254 [TBL] [Abstract][Full Text] [Related]
15. The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease. Lopez Lopez C; Tariot PN; Caputo A; Langbaum JB; Liu F; Riviere ME; Langlois C; Rouzade-Dominguez ML; Zalesak M; Hendrix S; Thomas RG; Viglietta V; Lenz R; Ryan JM; Graf A; Reiman EM Alzheimers Dement (N Y); 2019; 5():216-227. PubMed ID: 31211217 [TBL] [Abstract][Full Text] [Related]
16. The Trajectory of Cerebrospinal Fluid Growth-Associated Protein 43 in the Alzheimer's Disease Continuum: A Longitudinal Study. Zhang H; Lyu D; Jia J; J Alzheimers Dis; 2022; 85(4):1441-1452. PubMed ID: 34958042 [TBL] [Abstract][Full Text] [Related]
17. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease. Besson FL; La Joie R; Doeuvre L; Gaubert M; Mézenge F; Egret S; Landeau B; Barré L; Abbas A; Ibazizene M; de La Sayette V; Desgranges B; Eustache F; Chételat G J Neurosci; 2015 Jul; 35(29):10402-11. PubMed ID: 26203136 [TBL] [Abstract][Full Text] [Related]